12.49
前日終値:
$13.26
開ける:
$13.24
24時間の取引高:
89,951
Relative Volume:
0.79
時価総額:
$379.29M
収益:
-
当期純損益:
$-1.77M
株価収益率:
-83.99
EPS:
-0.1487
ネットキャッシュフロー:
$-1.46M
1週間 パフォーマンス:
-16.40%
1か月 パフォーマンス:
+28.37%
6か月 パフォーマンス:
+266.28%
1年 パフォーマンス:
+0.00%
Turn Therapeutics Inc Stock (TTRX) Company Profile
名前
Turn Therapeutics Inc
セクター
電話
(818) 564-4011
住所
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
TTRX
Turn Therapeutics Inc
|
12.49 | 379.29M | 0 | -1.77M | -1.46M | -0.1487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-29 | 開始されました | D. Boral Capital | Buy |
Turn Therapeutics Inc (TTRX) 最新ニュース
Turn Therapeutics (NASDAQ:TTRX) Cut to Sell at Wall Street Zen - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Stock Rating Upgraded by Lucid Cap Mkts - MarketBeat
Lucid Capital Markets initiates Turn Therapeutics stock with buy rating - Investing.com
Lucid Capital Markets initiates Turn Therapeutics stock with buy rating By Investing.com - Investing.com Canada
TTRX: Adaptive trial with pruritus-based enrichment shows strong efficacy in atopic dermatitis - TradingView
Turn Therapeutics at Stifel forum: itch score drives trial design By Investing.com - Investing.com Canada
Turn Therapeutics Inc.(NasdaqGM: TTRX) added to S&P TMI Index - marketscreener.com
Turn Therapeutics' (TTRX) "Sell" Rating Reaffirmed at WBB Securities - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Raised to "Hold" at Wall Street Zen - MarketBeat
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum - BioSpace
Turn Therapeutics to present at Stifel forum, previewing atopic dermatitis program - TradingView
Turn Therapeutics to Present Atopic Dermatitis Strategy - TipRanks
Former CDC Director Dr. Robert R. Redfield Named Chief Scientific Officer at Turn Therapeutics - The Dermatology Digest
Turn Therapeutics Names Former CDC Director Robert Redfield Chief Scientific Officer - citybiz
Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer - BioSpace
Turn Therapeutics Names Robert Redfield Chief Scientific Officer - TipRanks
Former CDC Director Robert Redfield Joins Turn Therapeutics as Chief Scientific Officer - Dermatology Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
TTRX - Finviz
Turn Therapeutics (NASDAQ:TTRX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Turn Therapeutics (TTRX) Surges 7.34% to $10.38 as Biotech Momentum AcceleratesBreakout Stock Alerts - careplusvn.com
Ieq Capital LLC Makes New Investment in Turn Therapeutics Inc. $TTRX - MarketBeat
Turn (TTRX) Levels: Records a 2.33% Increase to $9.68 in the Current Update; Levels: $9.20 and $10.16 Define the Nearby Reference Levels in the Latest SessionContinuation Pattern Picks - vinanet.vn
Turn (TTRX) Today: Closes 0.84% Lower at $9.46 at the Close; Next Test: the Price Remains Bounded by the Supplied Support and ResistanceAnalyst Upgrade Stocks - vinanet.vn
Turn (TTRX) Quarterly Results: Results Show Limited Variance From Forecasts under the Current Snapshot; Closing Move: The Share Price Sheds 0.84% on the DayBanking Earnings Report - careplusvn.com
Turn (TTRX) Session: Records a 0.84% Decrease to $9.46 on the Day; Range Check: Traders Can Monitor the $8.99-$9.93 Range in the Available RecordFibonacci Entry Signals - vinanet.vn
Turn (TTRX) Results Breakdown: Available Metrics Are Broadly in Line for the Current Session; After Earnings: The Stock Ends Down 2.85% at the CloseGuidance Accuracy Score - vinanet.vn
Turn (TTRX) Close: Ends Lower by 0.20% at $9.80 on the Day; Current Setup: Traders Can Monitor the $9.31-$10.29 Range in Latest TradingWedge Breakout - vinanet.vn
GX-03 Selectively Reduces Key Drivers of Skin Inflammation, Itch - The Dermatology Digest
GX-03 Cuts Itch-Related Cytokine IL-31 by Nearly 68% in AD Model - Dermatology Times
Turn Therapeutics publishes study on GX-03 skin therapy - Investing.com
Turn Therapeutics publishes study on GX-03 skin therapy By Investing.com - Investing.com India
Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch - Business Wire
Turn Therapeutics Issues 579,664 Shares in Cashless Warrant Exercise - Minichart
Form 8K Turn Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa
Turn Therapeutics Reports Unregistered Cashless Warrant Share Issuance - TipRanks
Turn Therapeutics Completes Cashless Exercise of GEM Warrant, Issues 579,664 Shares - Kalkine Media
Turn Therapeutics Raises $1.35 Million in Private Placement - Minichart
Turn Therapeutics Secures $1.35 Million Through Private Stock Placement - Kalkine Media
Turn Therapeutics Raises $1.35M Through Private Placement - TipRanks
Turn Therapeutics (TTRX) Rallies 3.55% to $9.91, Approaching Key $10.41 ResistanceBeta Neutral Pair - vinanet.vn
Ladenburg Thalmann Initiates Turn Therapeutics(TTRX.US) With Buy Rating, Announces Target Price $16 - Moomoo
Turn Therapeutics (NASDAQ:TTRX) Stock Price Down 6.5%Time to Sell? - MarketBeat
Turn Therapeutics Inc. announced that it expects to receive $1.35 million in funding - marketscreener.com
Turn Therapeutics (TTRX) Falls 5.6% to $9.95 as Support at $9.45 Comes into FocusRetracement Entry - vinanet.vn
Turn Therapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Long-Term Debt - Kalkine Media
Form 8K Turn Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Turn Therapeutics (NASDAQ: TTRX) posts larger loss, adds debt and warns on going concern - Stock Titan
Turn Therapeutics Q2 net loss per share widens on higher R&D costs - TradingView
Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results - Yahoo Finance
Turn Therapeutics Inc (TTRX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):